Related Experiment Video
Updated: Jul 10, 2026
A 3D Digital Model for the Diagnosis and Treatment of Pulmonary Nodules
Published on: May 19, 2023
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster1, Martin Dreyling, Wolfram Klapper
1Department of Internal Medicine III, University of Munich, Germany.
Abstract:
There is no generally established prognostic index for patients with mantle cell lymphoma (MCL), because the International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) have been developed for diffuse large cell and follicular lymphoma patients, respectively. Using data of 455 advanced stage MCL patients treated within 3 clinical trials, we examined the prognostic relevance of IPI and FLIPI and derived a new prognostic index (MCL international prognostic index, MIPI) of overall survival (OS). Statistical methods included Kaplan-Meier estimates and the log-rank test for evaluating IPI and FLIPI and multiple Cox regression for developing the MIPI. IPI and FLIPI showed poor separation of survival curves. According to the MIPI, patients were classified into low risk (44% of patients, median OS not reached), intermediate risk (35%, 51 months), and high risk groups (21%, 29 months), based on the 4 independent prognostic factors: age, performance status, lactate dehydrogenase (LDH), and leukocyte count. Cell proliferation (Ki-67) was exploratively analyzed as an important biologic marker and showed strong additional prognostic relevance. The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL.
Insights
A new prognostic index, the MCL International Prognostic Index (MIPI), has been developed for mantle cell lymphoma (MCL) patients. MIPI effectively categorizes patients into low, intermediate, and high-risk groups for improved treatment decisions.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Established prognostic indices like IPI and FLIPI are not suitable for mantle cell lymphoma (MCL).
- There is a need for a specific prognostic tool for advanced stage MCL patients.
Purpose of the Study:
- To evaluate the prognostic relevance of existing indices (IPI, FLIPI) in MCL.
- To develop and validate a new prognostic index (MIPI) for advanced stage MCL.
Main Methods:
- Analysis of data from 455 advanced stage MCL patients across 3 clinical trials.
- Utilized Kaplan-Meier estimates, log-rank tests, and multiple Cox regression.
- Identified independent prognostic factors including age, performance status, LDH, and leukocyte count.
Main Results:
- IPI and FLIPI demonstrated poor survival curve separation in MCL patients.
- The developed MIPI classified patients into low (44%), intermediate (35%), and high-risk (21%) groups.
- Median overall survival (OS) was not reached for low-risk, 51 months for intermediate, and 29 months for high-risk groups.
- Ki-67 showed significant additional prognostic value.
Conclusions:
- The MIPI is the first prognostic index specifically designed for MCL patients.
- MIPI offers improved risk stratification for advanced stage MCL.
- MIPI can aid in guiding risk-adapted treatment strategies for MCL.
